| Iliannie Rodriguez Chaluisant, MD | |
|
1490 Se Magnolia Ext, Ocala, FL 34471-4443 | |
| (352) 351-7200 | |
| (352) 671-4393 |
| Full Name | Iliannie Rodriguez Chaluisant |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 9 Years |
| Location | 1490 Se Magnolia Ext, Ocala, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336512946 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | ME145985 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Ocala | Ocala, FL | Hospital |
| Marion Communtiy Hospital | Ocala, FL | Hospital |
| Bayfront Health Seven Rivers | Crystal river, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Imaging Center Of Ocala Llp | 0345130787 | 36 |
| Radiology Imaging Associates, Llc | 2466342803 | 74 |
| Inverness Medical Imaging Llc | 3870590672 | 66 |
| Ocala Health Imaging Services Llc | 8224217179 | 31 |
| Timberridge Imaging Center | 9436049863 | 34 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | University Of Florida Jacksonville Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144276452 PECOS PAC ID: 9133025869 Enrollment ID: O20040128000786 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | Timberridge Imaging Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669460473 PECOS PAC ID: 9436049863 Enrollment ID: O20040318000633 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | Medical Imaging Center Of Ocala Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669469045 PECOS PAC ID: 0345130787 Enrollment ID: O20040318000671 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | Radiology Imaging Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063400729 PECOS PAC ID: 2466342803 Enrollment ID: O20040318000719 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | Inverness Medical Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093763591 PECOS PAC ID: 3870590672 Enrollment ID: O20061108000195 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | Ocala Health Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023318060 PECOS PAC ID: 8224217179 Enrollment ID: O20110124001037 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | St Thomas Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659385011 PECOS PAC ID: 0042235137 Enrollment ID: O20201204000710 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Entity Name | Community Imaging Alliance Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194466854 PECOS PAC ID: 6305227190 Enrollment ID: O20220726001435 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Iliannie Rodriguez Chaluisant, MD Po Box 21643, Tampa, FL 33622-1643 Ph: (352) 671-4300 | Iliannie Rodriguez Chaluisant, MD 1490 Se Magnolia Ext, Ocala, FL 34471-4443 Ph: (352) 351-7200 |
News Archive
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.
Symptoms of an enlarged prostate — known medically as benign prostatic hyperplasia (BPH) — can range from a weak, slow urinary stream, to hesitancy and straining to urinate, to an inability to empty the bladder completely, to more serious complications including recurrent urinary tract infections and kidney damage.
Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
› Verified 9 days ago
Ralf Richard Barckhausen, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1818 Sw 15th Ave, Ocala, FL 34474 Phone: 352-671-4300 Fax: 352-671-4393 | |
Edson Gil Cortes, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1818 Sw 15th Ave, Ocala, FL 34474 Phone: 352-671-4300 Fax: 352-671-4393 | |
Malcolm Edward Williamson Ii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1818 Sw 15th Ave, Ocala, FL 34474 Phone: 352-671-4300 Fax: 352-671-4393 | |
Dr. Luis A Jimenez, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 6035 Sw 54th St, Suite 101, Ocala, FL 34474 Phone: 352-857-9132 | |
Caleb Ruben Rivera, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1818 Sw 15th Ave, Ocala, FL 34474 Phone: 352-671-4300 Fax: 352-671-4393 | |
Dr. Lourdes I Montes, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1901 Se 18th Ave Ste 200, Ocala, FL 34471 Phone: 352-671-4252 | |
Dr. Chintan Desai, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1714 Sw 17th St Ste 300, Ocala, FL 34471 Phone: 352-274-9565 Fax: 352-342-9038 |